Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Venous Thromboembolism 8Venous Thrombosis 5Pulmonary Embolism 5Neoplasms 4Thromboembolism 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Thrombosis 1Thrombophilia 1Thrombocythemia, Essential 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Pancreatic Neoplasms 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Myeloma 1Monoclonal Gammopathy of Undetermined Significance 1Mesenteric Ischemia 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1

Interventions

apixaban 2Dalteparin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Intracranial Thrombosis × Dalteparin × Clear all
NCT02585713 2020-08-04

Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism

Academic and Community Cancer Research United

Phase 3 Completed
300 enrolled 11 charts
Classical hematology

Neoplasm Metastasis, Neoplasms, Pulmonary Embolism, Venous Thrombosis, Intracranial Thrombosis, Venous Thromboembolism, Mesenteric Ischemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡